Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites.
The effect of two repeated oral doses of 100 mg tofisopam 15 mg midazolam and placebo on the concentrations of monoamine metabolites (MHPG, 5-HIAA, HVA) in lumbar CSF were studied in general surgical patients operated on under spinal analgesia (n = 12 in each group). Midazolam, but not tofisopam, improved the quality of sleep the night before surgery. Both active agents reduced preoperative anxiety of the patients, but tofisopam was without subjective sedative action. In the placebo group, in contrast to the active drug groups, there was a slight positive correlation between the MHPG concentration and degree of anxiety before surgery. The only significant difference in the monoamine metabolites in lumbar CSF was found in the concentrations of HVA between tofisopam and placebo treated patients. The lower HVA concentrations suggest that the curious 3,4-benzodiazepine derivative, tofisopam, modifies central dopaminergic activity.
M
M
Hovi-Viander
J
J
Kanto
H
H
Scheinin
M
M
Scheinin
D000368:Aged; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology*; D001679:Biogenic Amines / Q000134:cerebrospinal fluid*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008874:Midazolam; D008875:Middle Aged; D012890:Sleep / Q000187:drug effects
D014151:Anti-Anxiety Agents; D001679:Biogenic Amines; D006993:Hypnotics and Sedatives; D001569:Benzodiazepines; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D008874:Midazolam; C012582:tofisopam; D006719:Homovanillic Acid